Eli Lilly secures exclusive rights to chronic pain treatment
03-06-2019
Jonathan Weiss / Shutterstock.com
San Francisco-based biotech company Atomwise could be set to receive up to $1 million per target in milestone payments following a partnership agreement with Eli Lilly.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Atomwise, artificial intelligence, AI, preclinical, milestones, drug discovery, patent licensing, Centrexion Therapeutics, chronic pain
